Fre­quen­cy fol­lows Astel­las pact with $62M round to bankroll PhII of lead re­gen­er­a­tive drug

A few days ago Fre­quen­cy Ther­a­peu­tics got some high pro­file en­dorse­ment on its small mol­e­cule strat­e­gy for re­gen­er­a­tive med­i­cine, when Astel­las of­fered $80 mil­lion up­front …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.